Anti-glioblastoma activity of monensin and its analogs in an organoid model of cancer.

ABSTRACT: Glioblastoma (GBM) remains the most frequently diagnosed primary malignant brain cancer in adults. Despite recent progress in understanding the biology of GBM, the clinical outcome for patients remains poor, with a median survival of approximately one year after diagnosis. One factor contributing to failure in clinical trials is the fact that traditional models used in GBM drug discovery poorly recapitulate patient tumors. Previous studies have shown that monensin (MON) analogs, namely esters and amides on C-26 were potent towards various types of cancer cell lines. In the present study we have investigated the activity of these molecules in GBM organoids, as well as in a host:tumor organoid model. Using a mini-ring cell viability assay we have identified seven analogs (IC₅₀ = 9

SUBMITTER: Urbaniak A 

PROVIDER: S-EPMC9472755 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature